Company: PRME
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038619
Chunk: 36

Company: Prime Medicine, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
436 — — 436 Issuance of common stock upon exercise of stock options9,664 — 36 — — 36 Stock-based compensation expense— — 5,209 — — 5,209 Change in unrealized loss on investments, net of tax— — — (80)— (80)Net loss— — — — (45,761)(45,761)Balance as of March 31, 2024120,021,274 2 780,950 (95)(537,091)243,766 Issuance of common stock upon exercise of stock options9,539 — 35 — — 35 Stock-based compensation expense— — 8,091 — — 8,091 Change in unrealized loss on investments, net of tax— — — 24 — 24 Net loss— — — — (55,327)(55,327)Balance as of June 30, 2024120,030,813 $2 $789,076 $(71)$(592,418)$196,589 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months EndedJune 30,(in thousands)20252024Cash flows used in operating activities:Net loss$(104,481)$(101,088)Adjustments to reconcile net loss to net cash used in operating activitiesStock-based compensation expense12,006 13,300 Non cash lease expense4,761 7,917 Depreciation expense3,564 2,853 Change in fair value of short-term investment — related party1,561 759 Amortization of premiums and discount on short-term investments(575)(2,079)Deferred income taxes— — Changes in operating assets and liabilities:Collaboration receivable — related party(120)— Prepaid expenses and other current assets652 (2,519)Accounts payable(1,461)(9,230)Accrued expenses and other current liabilities(1,690)(3,939)Accrued settlement payment — related party— (13,500)Deferred revenue — related party(2,433)— Lease liabilities